NCT02605265View on ClinicalTrials.gov

Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

PHASE3CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2023

Conditions
Locally Advanced Rectal Cancer
Interventions
RADIATION

Radiation

Pelvic Radiation: 50Gy/25Fx

DRUG

Capecitabine

DRUG

Irinotecan

DRUG

Oxaliplatin

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Hubei Cancer Hospital

OTHER

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Ruijin Hospital

OTHER

lead

Fudan University

OTHER

NCT02605265 - Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 | Biotech Hunter | Biotech Hunter